Current Trials and Studies
BRE437: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+, HER2- negative recurrent or metastatic breast cancer
For additional questions, feel free to contact:
Crystal Johnson
Clinical Research Coordinator, Supervisor
(573) 314-7365
Fax: 573-443-3627
[email protected]
Coby Ayers
Clinical Research Coordinator
(573) 441-3711
[email protected]
We are located at:
1705 E Broadway, Suite 100
Columbia, MO 65201
Phone: (573) 874-7800 We look forward to hearing from you and discussing how you can become a part of this important research.